evipedia.ai
← Back

PT-141 for Health & Longevity

Evidence Review created on 10/30/2026 using AI4L / Opus 5.5

Also known as: Bremelanotide, Bremelanotide Acetate, Vyleesi, PT141

Motivation

PT-141 (bremelanotide) is a lab-made chain of amino acids modeled on a natural brain hormone that helps regulate skin color, appetite and sexual interest. It is injected under the skin shortly before sexual activity and works on brain circuits involved in desire rather than on blood flow. It draws interest from health-focused adults because sexual well-being is part of quality of life over the decades, and because the same brain pathway also shapes appetite and body weight.

The compound grew out of a sunless tanning project in the 1980s, after volunteers reported unexpected sexual effects. It was later approved in the United States (Vyleesi prescribing label) for distressing low sexual desire in women before menopause, and it is now widely sold by wellness clinics and online vendors to men, older women and others outside that approval.

This review examines what human studies show about its benefits and harms, how strong and how independent that evidence is, and what is known about use outside the approved group, including dosing, monitoring and product quality.

Benefits - Risks - Protocol - Conclusion

Five items giving high-level views of PT-141, its brain mechanism and the dispute over its efficacy for hypoactive sexual desire disorder (HSDD, persistent low sexual desire that causes distress).

No dedicated content was found from Rhonda Patrick, Chris Kresser, Life Extension Magazine or Lifespan.io; their on-site searches and web searches returned no freely accessible article on PT-141 or bremelanotide.

Grokipedia

Bremelanotide

AI-written overview of chemistry, approval and dosing; it states that phase 3 trials increased satisfying sexual events, which the U.S. Food and Drug Administration (FDA) label contradicts (FDA label).

Examine

No Examine article on PT-141 or bremelanotide exists. Examine.com does not typically cover prescription medications, and bremelanotide is a prescription drug.

ConsumerLab

No ConsumerLab article on PT-141 or bremelanotide exists. ConsumerLab does not typically cover prescription medications.

Systematic Reviews

Four systematic reviews or meta-analyses cover bremelanotide’s efficacy, its tolerability and the placebo response in female sexual dysfunction.

Mechanism of Action

Bremelanotide is a synthetic ring-shaped chain of seven amino acids modeled on alpha-melanocyte-stimulating hormone (α-MSH, a natural hormone controlling pigmentation, appetite and sexual behavior). It is a non-selective melanocortin receptor agonist (a compound that switches on melanocortin receptors), with the potency order MC1R > MC4R > MC3R > MC5R > MC2R (receptor subtypes 1 to 5); at therapeutic doses, MC1R (the receptor on pigment cells) and MC4R matter most (FDA label).

  • Desire pathway: In animal studies (narrative review), MC4R activation in the medial preoptic area (a brain area governing sexual behavior) increases release of dopamine (an excitatory brain messenger) (Pfaus 2022). The label calls the mechanism in women unknown.
  • Brain imaging: In women with HSDD, a single dose changed responses to erotic images in sensory and emotional brain regions (partly AMAG-funded trial, Thurston 2022).
  • Side-effect pathways: MC1R activation darkens skin (review: Sweeney 2023); MC4R activation causes nausea and suppresses appetite (Thurston 2022) and transiently raises blood pressure (sponsor co-authored trial, White 2017).
  • Competing view: Independent critics argue the resulting effects are small (Spielmans 2024).
  • Pharmacology: Subcutaneous bioavailability (fraction reaching the bloodstream) is about 100%, plasma levels peak at about 1 hour, and half-life is about 2.7 hours (1.9–4.0). It is 21% protein-bound with a 25 L volume of distribution (how widely it spreads in the body), and it is broken down by peptide hydrolysis (cutting of amino-acid bonds) rather than by cytochrome P450 (CYP, liver drug-metabolizing) enzymes; excretion is mainly urinary (64.8%) (FDA label).

Historical Context & Evolution

Bremelanotide descends from melanotan II, a sunless tanning peptide developed at the University of Arizona. Volunteers reported spontaneous erections, and a small crossover trial confirmed erections in men with psychogenic erectile dysfunction (erection problems without a physical cause) (Wessells 1998). Palatin Technologies developed PT-141, a close analog, first for men (Molinoff 2003).

Early Palatin-run intranasal and subcutaneous trials in men showed erectile responses (Diamond 2004; Rosen 2004). In 2007, Palatin and partner King Pharmaceuticals delayed a phase 3 erectile dysfunction trial after FDA raised blood pressure concerns (reported by Fierce Biotech report; FDA’s communications to the sponsor are not public). A 2008 trial in women was later retracted (Safarinejad 2008), and a 2008 trial in men carries an expression of concern (Safarinejad 2008); neither is used as evidence here.

Development pivoted to on-demand subcutaneous dosing in women. A Palatin-funded phase 2b trial with Palatin co-authors (Clayton 2016) and two phase 3 randomized controlled trials (RCTs), funded by Palatin and AMAG (Kingsberg 2019), led to FDA approval in 2019 for premenopausal women with acquired, generalized HSDD (FDA label); Cosette now holds the application (Drugs@FDA application record).

Opinion has since split. Independent analysts contested clinical meaningfulness (Spielmans 2021), and trial investigators, with Palatin employees as co-authors, rebutted the reanalysis (Kingsberg 2021). An investigator-led imaging trial, partly funded by AMAG, supported a central effect (Thurston 2022), while health-optimization clinics and research-chemical vendors expanded off-label use.

Expected Benefits

No human study has measured lifespan, biological aging markers or other longevity outcomes with bremelanotide.

High 🟩 🟩 🟩

In two identical 24-week phase 3 RCTs in 1,247 premenopausal women, as-needed 1.75 mg injections raised desire and lowered distress about low desire versus placebo (Kingsberg 2019, sponsor-funded). An investigator-led Imperial College crossover trial (Thurston, Dhillo; 31 women; partly AMAG-funded) found more women reporting increased desire within 24 hours (Thurston 2022). Gains are consistent but small, and critics question the questionnaires’ validity (Spielmans 2024). No trial enrolled men or postmenopausal women.

Magnitude: Integrated difference versus placebo of +0.35 points on the Female Sexual Function Index desire domain (FSFI, scored 1.2–6.0) and −0.33 points on item 13 of the Female Sexual Distress Scale–Desire/Arousal/Orgasm (FSDS-DAO, distress scored 0–4); standardized effect sizes (differences in standard-deviation units) were 0.39 and 0.27 (Kingsberg 2019).

Medium 🟩 🟩

Sexual Arousal and Overall Sexual Function in Women ⚠️ Conflicted

A meta-analysis found that bremelanotide improved arousal and total FSFI scores (Toledo 2026), but all pooled trials come from one sponsor program (Palatin), such as the phase 2b trial in 327 premenopausal women (Clayton 2016). An independent reanalysis of unpublished phase 3 outcomes, including FSFI arousal and total scores, found nil-to-small effects (Spielmans 2024). The net reading is a real but small improvement in arousal and overall function.

Magnitude: FSFI total score rose 3.6 points with pooled 1.25/1.75 mg versus 1.9 points with placebo over 12 weeks, a statistically significant difference (Clayton 2016).

Erectile Response in Men

Palatin’s small crossover trials recorded erections above placebo, measured by penile rigidity monitoring, after subcutaneous doses above 1.0 mg in healthy men and 4–6 mg in men with inadequate sildenafil response (Rosen 2004), and after intranasal doses above 7 mg (Diamond 2004). Low-dose intranasal PT-141 plus sildenafil (a PDE5 inhibitor, the drug class that prolongs penile blood-vessel relaxation) outperformed sildenafil alone (Palatin-authored trial, Diamond 2005). No phase 3 trial in men exists.

Magnitude: Erectile activity exceeded placebo at subcutaneous doses above 1.0 mg and intranasal doses above 7 mg; the published reports give statistical significance, and the literature reports no outcome figure for bremelanotide (Rosen 2004).

Body Weight and Food Intake

In two Palatin phase 1 RCTs in premenopausal women with obesity, repeated injections (three times daily for 15 days, or 2.5 mg plus 2.0 mg daily) cut intake by about 400 kcal per day and lowered weight versus placebo (Spana 2022). The Imperial College trial also recorded reduced food intake after one dose (Thurston 2022). A company-reported trial adding bremelanotide to tirzepatide (a GLP-1/GIP receptor agonist, an injectable weight-loss drug mimicking two gut hormones) reported added weight loss (Palatin press release). Evidence applies to repeated daily dosing, not on-demand use.

Magnitude: −1.3 kg versus placebo after 16 days of three-times-daily dosing (95% CI, the confidence interval likely to contain the true effect, −1.9 to −0.8) (Spana 2022).

Low 🟩

Frequency of Satisfying Sexual Events ⚠️ Conflicted

The phase 2b trial found more satisfying sexual events per month with pooled 1.25/1.75 mg than placebo (Clayton 2016). The larger phase 3 trials found no difference (FDA label; critique by Mintzes 2021). The stronger phase 3 evidence indicates no change in the frequency of satisfying sexual events.

Magnitude: Phase 3 mean change 0.0 versus −0.1 events per month (Study 1) and 0.0 versus 0.0 (Study 2), both not significant (FDA label); phase 2b +0.7 versus +0.2 per month (Clayton 2016).

Speculative 🟨

Glioblastoma Cell Growth Inhibition

In cultured glioblastoma (aggressive brain tumor) cells, bremelanotide lowered survivin (a cell-survival protein) and triggered cell death via MC3R and MC4R (Suzuki 2024). The basis is in-vitro only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. Loss-of-function variants in MC4R (the gene encoding the appetite- and desire-regulating receptor) cause inherited obesity, but whether carriers respond differently to bremelanotide is unstudied.
  • Baseline biomarkers: In sponsor co-authored phase 3 subgroup analyses (Palatin, AMAG), gains in desire and distress held across baseline bioavailable testosterone quartiles, body weight and body mass index (BMI, weight relative to height) groups, with few exceptions (Simon 2022).
  • Hormonal contraception: Desire gains were statistically significant in women not using hormonal contraceptives and only numerically larger than placebo in users (Simon 2022).
  • Sex: Desire benefits are shown only in premenopausal women; in men only short-term erectile responses were measured, and no trial has tested desire (Rosen 2004).
  • Pre-existing conditions: Benefit was shown in acquired, generalized HSDD not caused by a medical or psychiatric condition, relationship problems or medications (FDA label); benefit in antidepressant-related or pain-related low desire is unknown.
  • Age: Trial participants were 19–56 years old (mean 39) (FDA label); no efficacy data exist for postmenopausal women or older men.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Nausea and Vomiting

Nausea is the most common adverse event and a known effect of MC4R activation. In the sponsor’s phase 3 trials, 13% needed antiemetic (anti-nausea) medication and 8% discontinued because of it; incidence fell from 21% after the first dose to about 3% afterward (FDA label; Kingsberg 2019). The investigator-led Imperial College trial (Thurston, Dhillo) also recorded more nausea than placebo (Thurston 2022). Overall discontinuation for adverse events was 18% versus 2%.

Magnitude: Nausea 40.0% versus 1.3% with placebo; vomiting 4.8% versus 0.2% with placebo (FDA label; sponsor safety review, Clayton 2022).

Medium 🟥 🟥

Transient Blood Pressure Rise and Heart Rate Drop

Each dose briefly raises blood pressure and lowers heart rate, peaking 2–4 hours after injection and usually resolving within 12 hours, without accumulation over 16 daily doses (FDA label). An ambulatory monitoring RCT in 397 women with normal or controlled blood pressure confirmed small transient increases (White 2017, sponsor co-authored). The label contraindicates use in uncontrolled hypertension or known cardiovascular disease.

Magnitude: Ambulatory systolic pressure 3.1–3.2 mmHg higher than placebo 0–4 hours after 1.75 mg, with heart rate 4.6–4.7 beats per minute lower (White 2017); label maximum increase 6 mmHg systolic and 3 mmHg diastolic.

Flushing

Facial or body flushing is the second most common adverse event, usually mild and transient; few events were severe and 1% discontinued (FDA label). It was also among the most common events in Palatin’s trials in men (Diamond 2004).

Magnitude: 20.3% versus 0.3% with placebo (FDA label); the sponsor’s safety review abstract gives 1.3% for placebo (Clayton 2022).

Headache

Headache occurred more often than with placebo in the phase 3 trials. One case was serious (hospitalization for intractable pain), and 1% of users discontinued because of headache (FDA label).

Magnitude: 11.3% versus 1.9% with placebo (Clayton 2022).

Focal Hyperpigmentation

MC1R activation stimulates melanin, producing darkened patches (focal hyperpigmentation) on the face, gums and breasts. It was rare at up to 8 doses per month, but daily dosing produced patches in over one-third of participants, and resolution after stopping was not confirmed in all (FDA label; Clayton 2022). Darker skin and frequent dosing, as in weight-loss regimens, raise risk.

Magnitude: 1% versus 0% with placebo at up to 8 monthly doses; 38% after 8 consecutive daily doses (no control group) (FDA label).

Injection Site Reactions

Pain, redness, bruising, itching or numbness at the injection site occurred more often than with placebo injections, and 1% discontinued (FDA label). The sponsor’s safety review, using a narrower definition, reported lower rates (Clayton 2022).

Magnitude: 13.2% versus 8.4% with placebo under the label’s broad definition (FDA label); 5.4% versus 0.5% under the narrower definition (Clayton 2022).

Fatigue, Dizziness and Other Less Common Reactions

Several milder reactions occurred more often than with placebo in the phase 3 trials, including cough, fatigue, hot flush, paresthesia (tingling skin), dizziness and nasal congestion (FDA label). Rarer events included muscle pain, restless legs and raised creatine phosphokinase (a muscle enzyme). Serious adverse events were uncommon in both groups (Kingsberg 2019).

Magnitude: Fatigue 3.2% versus 0.5%, dizziness 2.2% versus 0.5%, cough 3.3% versus 1.3%, paresthesia 2.6% versus 0.0% and nasal congestion 2.1% versus 0.5% with placebo; serious adverse reactions 1.1% versus 0.5% (FDA label).

Low 🟥

Acute Hepatitis

One woman developed acute hepatitis (liver inflammation; liver enzymes over 40 times the upper limit of normal) after 10 doses in the open-label extension; it resolved within 4 months, and a drug role could not be excluded (FDA label). Serious adverse events were few program-wide (Clayton 2022).

Magnitude: 1 case among 684 open-label extension participants (no control group) (FDA label; Palatin/AMAG-funded extension, Simon 2019).

Mole Changes and Melanoma

Case reports link the analog melanotan II, which also activates MC1R, to darkening or newly erupting moles and to melanoma (skin cancer) (Hjuler 2014; reviewed in Habbema 2017). No case with bremelanotide is published; the evidence is indirect (different compound, unregulated doses).

Magnitude: Not quantified in available studies. Only case reports with a related compound exist.

Priapism

Ischemic priapism (a painful erection that does not subside, cutting off penile blood flow) has been reported after melanotan II injection, in one case requiring surgery (Mallory 2021; Dreyer 2019). No bremelanotide case is published; evidence is indirect (analog compound).

Magnitude: Not quantified in available studies. Only case reports with a related compound exist.

Speculative 🟨

Fetal Harm

In dogs, bremelanotide raised pregnancy loss after implantation at 16 or more times human exposure, and mice showed delayed offspring development (FDA label). The basis is animal data only.

Long-Term Cardiovascular Effects of Repeated Pressure Rises

Whether years of frequent transient blood pressure rises affect heart attack or stroke risk is unknown; trial exposure lasted up to 18 months (Clayton 2022). The basis is mechanistic.

Risk-Modifying Factors

  • Genetic polymorphisms: Not studied. Fair-skinned carriers of MC1R variants (gene for the pigment-cell receptor) already have higher melanoma risk; how MC1R stimulation interacts with these variants is unknown (inferred from mechanism).
  • Baseline biomarkers: Elevated baseline blood pressure adds to each dose’s transient rise; an estimated glomerular filtration rate (eGFR, a kidney-function estimate) below 30 mL/min/1.73 m² doubles exposure and may increase nausea (FDA label).
  • Sex: Label risks were characterized in women; men face an inferred priapism risk, based on melanotan II case reports (Mallory 2021) and bremelanotide’s erectile effect.
  • Pre-existing conditions: Uncontrolled hypertension and known cardiovascular disease are contraindications; moderate liver impairment raises exposure 1.7-fold; darker skin raises hyperpigmentation risk (FDA label). Atypical moles or prior melanoma warrant caution (inferred).
  • Age: Safety in geriatric patients is not established and trials stopped at age 56 (FDA label); rising cardiovascular risk with age makes the pressure effect more relevant for older users (inferred).

Key Interactions & Contraindications

Documented interactions:

  • Oral naltrexone (for alcohol or opioid dependence): Avoid. Bremelanotide significantly lowers naltrexone exposure, risking treatment failure (FDA label; sponsor safety review, Clayton 2022). Non-oral naltrexone was not studied.
  • Oral drugs needing threshold concentrations (antibiotics such as amoxicillin, doxycycline): Avoid. Slowed gastric emptying may reduce their absorption and effect; the label instructs avoiding bremelanotide with them (FDA label).
  • Indomethacin and other quick-onset oral pain medications (including over-the-counter ibuprofen, naproxen): Lower, delayed exposure slows pain relief; the label suggests stopping bremelanotide when rapid onset is needed (FDA label; sponsor safety review, Clayton 2022).
  • Alcohol: No pharmacokinetic (blood-level) interaction and no excess low blood pressure with 0.6 g/kg ethanol; headache was more frequent than with bremelanotide alone (Palatin co-authored phase 1 trial, Clayton 2017).
  • Sildenafil: Co-administration in men produced no new or more frequent adverse events and a stronger erectile response than sildenafil alone (Diamond 2005).
  • Ondansetron (antiemetic): Pretreatment 30 minutes before dosing did not reduce bremelanotide-related nausea (FDA label).
  • Tirzepatide: In an 8-week sponsor trial, adding daily bremelanotide increased weight loss without reported excess tolerability problems; results are company-reported only (Palatin press release).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Decongestants and stimulants (pseudoephedrine, phenylephrine, amphetamines): Additive transient blood pressure rise, inferred from bremelanotide’s pressor (blood-pressure-raising) effect; separating dosing from the 2–4-hour peak limits overlap.
  • Antihypertensives (blood-pressure-lowering drugs; amlodipine, lisinopril): The pressor effect may briefly offset blood pressure control after each dose; home readings 2–4 hours post-dose show whether control holds.
  • Other melanocortin agonists (melanotan II, setmelanotide, afamelanotide): Additive skin darkening, nausea and blood pressure effects from shared receptor activation; concurrent use multiplies exposure.
  • GLP-1 receptor agonists (semaglutide, liraglutide): Additive nausea and slowed gastric emptying from overlapping gut effects; starting one agent at a time separates side effects.
  • Blood-pressure-raising supplements (yohimbine, licorice root, bitter orange/synephrine, high-dose caffeine): Additive pressor effect; avoiding them on dosing days removes overlap.
  • Niacin (nicotinic acid) supplements: Additive flushing through separate blood-vessel-widening pathways; separating doses reduces stacked flushing.
  • Vigorous exercise in the post-dose window (other intervention): Additive transient blood pressure load during the 2–4-hour peak; scheduling training outside that window limits overlap.

Populations who should avoid PT-141:

  • Uncontrolled hypertension or known cardiovascular disease: Absolute contraindication per label (FDA label).
  • High cardiovascular risk: The label does not recommend use in patients at high cardiovascular risk (FDA label).
  • Pregnancy or suspected pregnancy: The label calls for discontinuation if pregnancy is suspected and for effective contraception during use, based on animal fetal harm (FDA label).
  • Breastfeeding: No data on milk transfer or infant effects; the label asks for benefit-risk weighing (FDA label).
  • People taking oral naltrexone for alcohol or opioid dependence: Risk of addiction-treatment failure (FDA label).
  • Severe kidney impairment (eGFR <30 mL/min/1.73 m²) or severe liver impairment (Child-Pugh C, score 10–15, the most severe liver class): Kidney impairment doubles exposure; liver impairment is unstudied; the label warns of more frequent, severe nausea and vomiting (FDA label).
  • History of melanoma or atypical (dysplastic) moles: Inferred from MC1R-driven pigment stimulation and melanotan II case reports; no human data for bremelanotide.
  • Men at risk of priapism (e.g., sickle cell disease): Inferred from melanotan II priapism reports and bremelanotide’s erectile effect; no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Respecting dose limits: No more than one 1.75 mg dose per 24 hours and 8 per month limits additive blood pressure effects and focal hyperpigmentation (FDA label).
  • Cardiovascular screening: Blood pressure is checked before starting and periodically, with control below 130/80 mmHg as the ACC/AHA (American College of Cardiology/American Heart Association; members earn no PT-141 revenue) guideline target (Whelton 2018), reducing exaggerated pressor risk in hypertension.
  • Trial first dose: Nausea is most frequent after the first dose (21%) and falls to about 3% later (FDA label); a first dose away from planned sexual activity limits nausea’s impact.
  • Antiemetic plan: Ondansetron pretreatment did not prevent nausea (FDA label); antiemetics after nausea onset (not formally studied) address persistent nausea and vomiting.
  • Avoiding daily dosing: Daily dosing produced hyperpigmentation in 38% within 8 days (FDA label); on-demand use at labeled frequency prevents most pigment changes.
  • Skin surveillance: Baseline photographs and checks every 3 months; stopping at first focal darkening, as the label suggests (FDA label), limits persistent hyperpigmentation and flags mole changes early.
  • Separating oral medications: Avoiding co-use with threshold-dependent oral antibiotics, or spacing doses several hours apart, mitigates reduced absorption from slowed gastric emptying.
  • Pharmaceutical-grade sourcing: The FDA-approved autoinjector avoids the contamination and misdosing risk of research-grade vials, which FDA treats as unapproved drugs (FDA warning letter).
  • Contraception: Effective contraception during use mitigates the fetal-harm risk seen in animals (FDA label).
  • Stopping without benefit: Discontinuation after 8 weeks without improvement prevents ongoing exposure to side effects without gain (FDA label).
  • Prolonged erection response: Any erection that will not subside is treated as an emergency, limiting tissue damage from priapism reported with melanotan II (Mallory 2021).

Therapeutic Protocol

Timing, titration and cycling parameters without a citation reflect common practice.

  • Label regimen (premenopausal women with HSDD): 1.75 mg subcutaneously in the abdomen or thigh by autoinjector, at least 45 minutes before anticipated sexual activity; at most one dose per 24 hours and 8 per month (FDA label).
  • Dose-finding range: The phase 2b trial tested 0.75, 1.25 and 1.75 mg; pooled 1.25/1.75 mg was effective, and 1.75 mg advanced to phase 3 (Clayton 2016).
  • Male research doses: Subcutaneous 4–6 mg in sildenafil non-responders (Rosen 2004); intranasal 7.5 mg with sildenafil 25 mg (Diamond 2005). No regimen is approved for men.
  • Weight-related research regimens: 2.5 mg plus 2.0 mg daily for 4-day periods (Spana 2022) or 1.25 mg daily with tirzepatide (Palatin press release); investigational and pigmentation-prone.
  • Clinic and vendor protocols: Wellness clinics and peptide vendors market compounded nasal sprays and vials at varying doses; no published trial or named practitioner protocol validates these alternatives.
  • Time of day: Timing follows anticipated sexual activity; the label leaves the window to individual experience of effect and nausea (FDA label), and desire rose for up to 24 hours in one trial (Thurston 2022).
  • Half-life: About 2.7 hours (range 1.9–4.0), with peak plasma levels about 1 hour after injection (FDA label).
  • Single versus split dosing: One on-demand dose; split dosing is unstudied, and the label advises against a second dose within 24 hours (FDA label).
  • Genetic factors: No pharmacogenetic guidance exists; because breakdown is by peptide hydrolysis, variants in CYP2D6 or CYP3A4 (liver enzymes metabolizing many drugs) are not expected to change dosing (inferred).
  • Sex: The labeled dose applies to premenopausal women only; doses for men come from early trials (Rosen 2004).
  • Age: Efficacy and safety are not established in geriatric patients; trial participants were 19–56 years old (FDA label).
  • Baseline biomarkers: Blood pressure is controlled before starting (FDA label); significant gains held across baseline testosterone quartiles, with few exceptions (Simon 2022).
  • Pre-existing conditions: No dose adjustment in mild to moderate kidney or liver impairment; caution in severe impairment (FDA label).

Discontinuation & Cycling

  • Duration of use: On-demand use is open-ended rather than lifelong by design; it was studied for up to 76 weeks (24-week trial plus 52-week extension) without new safety signals (Simon 2019).
  • Stopping rule: The label calls for discontinuation after 8 weeks if symptoms have not improved (FDA label).
  • Withdrawal effects: None reported; neither the label nor the extension study describes rebound or withdrawal symptoms after stopping.
  • Tapering: Not applicable; intermittent on-demand dosing with a 2.7-hour half-life allows abrupt stopping.
  • Cycling: No evidence that cycling preserves efficacy; desire gains were sustained over the 52-week extension without planned breaks (Simon 2019). The 8-dose monthly cap acts as a built-in limit.
  • Persisting pigmentation: Focal hyperpigmentation may not resolve after stopping (FDA label).

Sourcing and Quality

  • Approved product: Vyleesi 1.75 mg/0.3 mL single-dose autoinjector, held by Cosette Pharmaceuticals under new drug application 210557 (Drugs@FDA application record) and dispensed through specialty pharmacies (Medfinder access update).
  • Research-grade vendors: In August 2026, FDA classed a vendor’s “PT-141 Peptide (Bremelanotide)” as an unapproved new drug, alongside the vendor’s other research peptides (FDA warning letter).
  • Black-market products: Forensic laboratories had to identify bremelanotide and melanotan II in seized products sold to bodybuilders (Mestria 2021); identity, dose and sterility of such products are unverified.
  • Compounded products: Some compounding pharmacies prepare bremelanotide nasal sprays or injectable vials on prescription; compounded drugs are not FDA-approved, so FDA does not verify their quality before marketing (FDA compounding Q&A), and no independent quality ranking of compounders exists.
  • What to look for: For non-label products, a certificate of analysis with high-performance liquid chromatography purity, mass spectrometry identity, endotoxin (bacterial toxin) and sterility testing, plus a licensed pharmacy as supplier.
  • Storage: At or below 25 °C, protected from light and never frozen (FDA label); cloudy or discolored solution is discarded.

Practical Considerations

  • Time to effect: Plasma levels peak about 1 hour after injection, dosing is at least 45 minutes before sexual activity, and overall benefit is judged over 8 weeks (FDA label).
  • Common pitfalls: Expecting a PDE5-inhibitor-like erectile effect rather than a modest change in desire; repeat dosing within 24 hours; daily use for tanning or weight loss; a first dose right before a planned encounter; relying on research-grade vials.
  • Regulatory status: FDA-approved in 2019 only for premenopausal women with acquired, generalized HSDD; the label states it is not indicated for postmenopausal women, men or sexual-performance enhancement, so such use is off-label (FDA label).
  • Cost and access: Roughly $290 per autoinjector without insurance, specialty-pharmacy only, with prior authorization common (Medfinder access update); much cheaper unregulated products compete.
  • Payer incentives: Insurers have a financial incentive to restrict coverage of a costly on-demand drug often classed as lifestyle therapy, which can shape access, research funding and the drift toward unregulated products.
  • Sponsor-dominated evidence: Nearly all efficacy trials were funded or run by Palatin and AMAG, which profit from adoption (Kingsberg 2019); the main independent critiques come from academic analysts.

Interaction with Foundational Habits

  • Sleep: None documented. No trial measured sleep; dosing late at night places the 2–4-hour nausea and blood pressure peak near sleep onset (inferred), so earlier dosing keeps side effects within waking hours.
  • Nutrition: Blunting of appetite. Repeated dosing cut intake by about 400 kcal per day (Spana 2022); slowed gastric emptying may delay absorption of oral medications taken with meals. Alcohol showed no pharmacokinetic interaction (Clayton 2017); a light meal beforehand is commonly used against nausea (unstudied).
  • Exercise: Indirect. Vigorous training during the 2–4-hour post-dose window may stack exercise-related and drug-related blood pressure rises (inferred); no data exist on muscle growth, endurance or recovery.
  • Stress management: Indirect, potentially potentiating. Psychological factors often drive low desire; mindfulness-based CBT improved desire, arousal and orgasm in a meta-analysis (Toledo 2026). Combining CBT with bremelanotide has not been tested.

Monitoring Protocol & Defining Success

Baseline testing before the first dose establishes cardiovascular eligibility, pregnancy status and reference points: seated blood pressure and resting heart rate, a pregnancy test in women of reproductive potential, kidney and liver function, a full skin and mole examination with photographs, and a baseline desire questionnaire score.

Ongoing monitoring follows this cadence: blood pressure around the first dose (2–4 hours after injection) and then every 3–6 months; skin examination every 3 months during use; desire and distress scores at 8 weeks, when the label’s stopping rule applies, and then every 6 months; liver tests repeated only if symptoms such as jaundice or dark urine appear.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <130/80 mmHg (ACC/AHA treatment target, Whelton 2018) Safety check: uncontrolled hypertension rules out use ACC/AHA: American College of Cardiology/American Heart Association, whose members earn no revenue from PT-141 (Whelton 2018). Conventional reference range: normal <120/80 mmHg. Seated after 5 minutes’ rest; recheck 2–4 hours post-dose.
Resting heart rate 60–100 beats per minute (standard reference range) Safety check: each dose lowers heart rate transiently Falls by up to 5 beats per minute after dosing (FDA label); measure with blood pressure.
eGFR ≥90 mL/min/1.73 m² (standard reference range) Safety check: below 30 doubles exposure Derived from serum creatinine; no fasting needed; caution threshold from the FDA label.
ALT 7–55 U/L (standard reference range; laboratory-specific) Safety check: rise prompts stopping ALT: alanine aminotransferase, a liver enzyme; one acute hepatitis case in trials (FDA label); pair with bilirubin; no fasting needed.
Pregnancy test (hCG) Negative (standard reference range) Safety check: positive result stops use hCG: human chorionic gonadotropin, the pregnancy hormone; urine or serum; animal fetal harm per FDA label.
Skin and mole examination No established target; track new or darkening patches against baseline photographs Safety check: hyperpigmentation prompts stopping Face, gums and breasts are typical sites (FDA label); dermoscopy (magnified skin-surface examination) for changing moles.
FSFI desire domain score No established target; track change from own baseline Expected to change: primary efficacy marker The label’s responder threshold is an increase of at least 1.2 points from baseline (FDA label); pair with FSDS-DAO item 13 (responder threshold: a decrease of at least 1 point) for distress.
Body weight No established target; track change from own baseline Expected to change with repeated daily dosing Relevant only to daily regimens (Spana 2022); weigh at the same time of day, fasted.

Qualitative markers:

  • Frequency and intensity of sexual desire
  • Distress or bother about low desire
  • Satisfaction with sexual activity and the relationship
  • Nausea burden after each dose
  • Flushing, headache and injection-site comfort
  • Appetite changes

Emerging Research

  • No recruiting trials: As of October 2026, ClinicalTrials.gov lists no recruiting bremelanotide trials; the registered studies below have passed their completion dates.
  • Obesity co-administration (BMT-801, NCT06565611): Phase 2, 113 enrolled; registered completion March 2025 (registry status still active, not recruiting); company-reported 4.4% versus 1.6% placebo weight loss, unpublished (Palatin press release). Peer-reviewed confirmation would strengthen the weight benefit; a null publication would weaken it.
  • Diabetic kidney disease (BREAKOUT, NCT05709444): Open-label phase 2b, 16 enrolled, 8 completed; completed 2024; 71% had a >30% fall in urine protein-to-creatinine ratio, uncontrolled (Palatin press release). Positive controlled trials would add a kidney benefit; null results would close it.
  • Korean bridging trial (NCT04943068): Phase 3, 193 premenopausal women; completed May 2023, no results posted or published. Positive results would add a second sponsor and population for desire; null results would weaken the High grade.
  • Breast milk transfer (NCT06867835): Phase 4, 10 lactating women, single dose; completed November 2025, no results posted. Low transfer would narrow the breastfeeding caution; substantial transfer would strengthen it.
  • Use in men: A 2026 commentary asks whether bremelanotide should be considered for male arousal and desire disorders (Pfaus 2026); a positive trial in men would broaden relevance, a null one would confine it to women.
  • Outcome validity: Independent reanalyses question the validity and size of phase 3 effects (Spielmans 2021); trials using behavioral outcomes could weaken or strengthen the desire benefit.
  • Melanocortin metabolic research: Central MC4R agonism is being pursued for obesity and metabolic disease (Sweeney 2023); more selective agonists could deliver appetite effects without bremelanotide’s pigmentation.

Conclusion

PT-141 is a lab-made injectable compound that acts on brain receptors linked to sexual interest, appetite and skin color. Its approved use is narrow (Vyleesi prescribing label): on-demand treatment of distressing low sexual desire in women before menopause. In that group, the evidence that it raises desire and eases related distress is consistent across large manufacturer-funded studies and one smaller independently run study, but the gains are modest, and it did not increase how often women had satisfying sexual experiences. Benefits for arousal, erections in men and short-term appetite and weight reduction each rest on a single research program, any role against cancer is purely theoretical, and effects on aging have never been measured.

The harms are better described than the benefits. Nausea is common, especially after the first dose, and leads many users to stop. Each dose briefly raises blood pressure, which matters most for people with heart disease or poorly controlled pressure, and frequent use can leave lasting dark skin patches. Related tanning compounds have been tied to mole changes and prolonged, painful erections.

The evidence base is thin outside the approved group and is dominated by the manufacturers that paid for nearly all of the studies, while independent critics dispute how meaningful the measured changes are. For health-focused men, women after menopause and people seeking weight control, use rests on findings carried over from other groups, and many products sold online are unregulated, with uncertain identity, dose and purity.

Top - Benefits - Risks - Protocol